Novo provides update on the denecimig Biologics License Application (BLA) in the US
Novo Nordisk says the FDA extended its review while manufacturing-site remediation continues; the company reports no new action date.
TL;DR
- The FDA has not completed its review of Novo Nordisk's denecimig application and has not provided a new action date.
- Novo says the review extension is tied to remediation work at a manufacturing facility, not deficiencies in the submitted clinical efficacy or safety data.
- The company still targets a US launch in the first half of 2027, contingent on a regulatory decision.
Novo Nordisk said the FDA's review of denecimig, an investigational treatment for haemophilia A in adults and children, is ongoing. The company said the agency linked the extension to remediation activities at a manufacturing site and has not communicated a new timeline for regulatory action. [1] [2]
Novo said the FDA did not identify deficiencies in the clinical efficacy or safety data submitted with the application. Reuters also reported that the delay stems from manufacturing-site work; the information about the regulator's feedback comes from the company's account, rather than a separate FDA statement in the sources reviewed. [1] [2]
Why it matters
The update separates a manufacturing-readiness issue from the clinical evidence cited in the application, while leaving the timing of a decision uncertain. For the program, the next material milestone is resolution of the facility remediation and a new FDA action timeline; no approval has been announced.
Editor's note
The FDA feedback and the absence of clinical-data deficiencies are reported from Novo Nordisk's statement and independently covered by Reuters. This is a one-story edition because no other collected bio item met the same news relevance and independent-source threshold; no clinical guidance is offered.